Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease.

被引：0
|
作者：
Pozzi, Samantha [1 ]
Yan, Hua
Vallet, Sonia
Vaghela, Nileshwari
Fulciniti, Mariateresa
Cirstea, Diana
Santo, Loredana
Mukherjee, Siddhartha
Hideshima, Teru
Schirtzinger, Linda [2 ]
Kuhstoss, Stuart [2 ]
Munshi, Nikhil C.
Anderson, Kenneth C.
Scadden, David
Raje, Noopur [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：946 / 946
页数：1
相关论文
共 50 条
  • [41] ASSESSING TREATMENT RESPONSE IN MULTIPLE MYELOMA: IMPLICATIONS OF USING BONE MARROW PLASMA CELL CONTENT AS A MARKER OF DISEASE BURDEN
    Abou Hussein, A. K.
    Rajkumar, S. V.
    Dispenzieri, A.
    Gertz, M.
    Lacy, M.
    Buadi, F.
    Hayman, S.
    Dingli, D.
    Hwa, Y. L.
    Lust, J.
    Russell, S.
    Kapoor, P.
    Go, R.
    Kyle, R.
    Kumar, S.
    HAEMATOLOGICA, 2015, 100 : 506 - 507
  • [42] The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease
    Fu, Jing
    Li, Shirong
    Ma, Huihui
    Yang, Jun
    Brown, Lewis M.
    Pagnotti, Gabriel M.
    Weiss, Stephen J.
    Mapara, Markus Y.
    Lentzsch, Suzanne
    BLOOD, 2022, 140 : 9930 - 9931
  • [43] Multiple myeloma (MM) with deletion of 13q13 is characterized by increased bone marrow (BM) neovascularization -: Implications for treatment of high-risk disease.
    Drach, J
    Ackermann, J
    Obermair, A
    Chott, A
    Fuchs, K
    Schreiber, S
    Königsberg, R
    Kaufmann, H
    Urbauer, E
    Geissler, K
    Gisslinger, H
    Huber, H
    BLOOD, 1999, 94 (10) : 542A - 542A
  • [44] DCLK1 monoclonal antibody-based CAR-T cells as novel treatment strategy against multiple myeloma
    Sureban, Sripathi M.
    Berahovich, Robert
    Zhou, Hua
    Xu, Shirley
    Wu, Lijun
    Golubovskaya, Vita
    Qu, Dongfeng
    May, Randal
    Bannerman-Menson, Edwin
    Houchen, Courtney W.
    CANCER RESEARCH, 2019, 79 (13)
  • [45] Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease
    Kristensen, Ida B.
    Christensen, Jacob Haaber
    Lyng, Maria B.
    Moller, Michael B.
    Pedersen, Lise
    Rasmussen, Lars M.
    Ditzel, Henrik J.
    Abildgaard, Niels
    LEUKEMIA & LYMPHOMA, 2014, 55 (04) : 911 - 919
  • [46] miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease
    Rossi, Marco
    Pitari, Maria Rita
    Amodio, Nicola
    Di Martino, Maria Teresa
    Conforti, Francesco
    Leone, Emanuela
    Botta, Cirino
    Paolino, Francesco Maria
    Del Giudice, Teresa
    Iuliano, Eleonora
    Caraglia, Michele
    Ferrarini, Manlio
    Giordano, Antonio
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    JOURNAL OF CELLULAR PHYSIOLOGY, 2013, 228 (07) : 1506 - 1515
  • [47] Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma
    Eckmann, Jan
    Fauti, Tanja
    Biehl, Marlene
    Zabaleta, Aintzane
    Blanco, Laura
    Lelios, Iva
    Gottwald, Stefan
    Rae, Richard
    Lechner, Stefanie
    Bayer, Christa
    Dekempe, Quincy
    Osl, Franz
    Carrie, Nadege
    Kassem, Sahar
    Lorenz, Stefan
    Christopeit, Tony
    Carpy, Alejandro
    Bujotzek, Alexander
    Broeske, Ann-Marie
    Dekhtiarenko, Iryna
    Attig, Jan
    Kunz, Leo
    Cremasco, Floriana
    Adelfio, Roberto
    Fertig, Georg
    Dengl, Stefan
    Gassner, Christian
    Bormann, Felix
    Kirstenpfad, Claudia
    Kraft, Thomas
    Diggelmann, Sarah
    Knobloch, Melanie
    Hage, Carina
    Feddersen, Romi
    Heidkamp, Gordon
    Poeschinger, Thomas
    Mayoux, Maud
    Bernasconi, Luise
    Prosper, Felipe
    Dumontet, Charles
    Martinet, Ludovic
    Leclair, Stephane
    Xu, Wei
    Paiva, Bruno
    Klein, Christian
    Umana, Pablo
    BLOOD, 2025, 145 (02) : 202 - 219
  • [48] AGA2118, a Bispecific Monoclonal Antibody Neutralizing both Sclerostin and DKK1, Increased Bone Formation, Decreased Bone Resorption, and Led to Rapid BMD Gains in a First in Human, Single- and Multiple-Dose, Placebo-Controlled, Randomized Study
    Drake, Matthew T.
    Friend, Richard
    Zhang, Yilong
    Ke, Juan
    Li, Yunfeng
    Lankachandra, Manesha
    Zovein, Ann C.
    Ke, Hua Zhu
    Dere, Willard
    Dent, Ricardo
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 4 - 4
  • [49] A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)
    Padmanabhan, Swaminathan
    Beck, Joseph Thaddeus
    Kelly, Kevin R.
    Munshi, Nikhil C.
    Dzik-Jurasz, Andy
    Gangolli, Esha
    Ettenberg, Seth
    Miner, Kelly
    Bilic, Sanela
    Whyte, Winston
    Mehdi, Fazal
    Chiang, Lu-May
    Rae, Patricia Liz
    Spencer, Andrew
    Shah, Jatin
    Anderson, Kenneth C.
    Giles, Francis J.
    Stewart, A. Keith
    BLOOD, 2009, 114 (22) : 312 - 313
  • [50] PECULIARITIES AND HETEROGENEITIES OF EXTRAMEDULLARY DISEASE OF MULTIPLE MYELOMA IN THE ""NOVEL AGENTS ERA"". COMPARISON OF SOFT-TISSUE AND BONE-RELATED SHAPES IN A RETROSPECTIVE REAL-LIFE ANALYSIS
    Torti, L.
    Morelli, A.
    Bacci, F.
    Di Bartolomeo, P.
    HAEMATOLOGICA, 2018, 103 : 44 - 45
12345